232 related articles for article (PubMed ID: 27126531)
1. Intratracheal Gene Delivery of SERCA2a Ameliorates Chronic Post-Capillary Pulmonary Hypertension: A Large Animal Model.
Aguero J; Ishikawa K; Hadri L; Santos-Gallego CG; Fish KM; Kohlbrenner E; Hammoudi N; Kho C; Lee A; Ibáñez B; García-Alvarez A; Zsebo K; Maron BA; Plataki M; Fuster V; Leopold JA; Hajjar RJ
J Am Coll Cardiol; 2016 May; 67(17):2032-46. PubMed ID: 27126531
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy of AAV1.SERCA2a in monocrotaline-induced pulmonary arterial hypertension.
Hadri L; Kratlian RG; Benard L; Maron BA; Dorfmüller P; Ladage D; Guignabert C; Ishikawa K; Aguero J; Ibanez B; Turnbull IC; Kohlbrenner E; Liang L; Zsebo K; Humbert M; Hulot JS; Kawase Y; Hajjar RJ; Leopold JA
Circulation; 2013 Jul; 128(5):512-23. PubMed ID: 23804254
[TBL] [Abstract][Full Text] [Related]
3. Endobronchial Aerosolized AAV1.SERCA2a Gene Therapy in a Pulmonary Hypertension Pig Model: Addressing the Lung Delivery Bottleneck.
Bikou O; Tharakan S; Yamada KP; Kariya T; Aguero J; Gordon A; Mazurek R; Aikawa T; Kohlbrenner E; Fish KM; Hajjar RJ; Ishikawa K
Hum Gene Ther; 2022 May; 33(9-10):550-559. PubMed ID: 35293228
[TBL] [Abstract][Full Text] [Related]
4. Intra-tracheal gene delivery of aerosolized SERCA2a to the lung suppresses ventricular arrhythmias in a model of pulmonary arterial hypertension.
Strauss B; Sassi Y; Bueno-Beti C; Ilkan Z; Raad N; Cacheux M; Bisserier M; Turnbull IC; Kohlbrenner E; Hajjar RJ; Hadri L; Akar FG
J Mol Cell Cardiol; 2019 Feb; 127():20-30. PubMed ID: 30502350
[TBL] [Abstract][Full Text] [Related]
5. Combination Therapy with STAT3 Inhibitor Enhances SERCA2a-Induced BMPR2 Expression and Inhibits Pulmonary Arterial Hypertension.
Bisserier M; Katz MG; Bueno-Beti C; Brojakowska A; Zhang S; Gubara S; Kohlbrenner E; Fazal S; Fargnoli A; Dorfmuller P; Humbert M; Hata A; Goukassian DA; Sassi Y; Hadri L
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502015
[TBL] [Abstract][Full Text] [Related]
6. Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model.
Aguero J; Ishikawa K; Hadri L; Santos-Gallego C; Fish K; Hammoudi N; Chaanine A; Torquato S; Naim C; Ibanez B; Pereda D; García-Alvarez A; Fuster V; Sengupta PP; Leopold JA; Hajjar RJ
Am J Physiol Heart Circ Physiol; 2014 Oct; 307(8):H1204-15. PubMed ID: 25158063
[TBL] [Abstract][Full Text] [Related]
7. AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.
Bisserier M; Milara J; Abdeldjebbar Y; Gubara S; Jones C; Bueno-Beti C; Chepurko E; Kohlbrenner E; Katz MG; Tarzami S; Cortijo J; Leopold J; Hajjar RJ; Sassi Y; Hadri L
Mol Ther; 2020 Feb; 28(2):394-410. PubMed ID: 31879190
[TBL] [Abstract][Full Text] [Related]
8. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.
Kawase Y; Ly HQ; Prunier F; Lebeche D; Shi Y; Jin H; Hadri L; Yoneyama R; Hoshino K; Takewa Y; Sakata S; Peluso R; Zsebo K; Gwathmey JK; Tardif JC; Tanguay JF; Hajjar RJ
J Am Coll Cardiol; 2008 Mar; 51(11):1112-9. PubMed ID: 18342232
[TBL] [Abstract][Full Text] [Related]
9. Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation.
Beeri R; Chaput M; Guerrero JL; Kawase Y; Yosefy C; Abedat S; Karakikes I; Morel C; Tisosky A; Sullivan S; Handschumacher MD; Gilon D; Vlahakes GJ; Hajjar RJ; Levine RA
Circ Heart Fail; 2010 Sep; 3(5):627-34. PubMed ID: 20634484
[TBL] [Abstract][Full Text] [Related]
10. Effect of SERCA2a overexpression in the pericardium mediated by the AAV1 gene transfer on rapid atrial pacing in rabbits.
Kuken BN; Aikemu AN; Xiang SY; Wulasihan MH
Genet Mol Res; 2015 Oct; 14(4):13625-32. PubMed ID: 26535677
[TBL] [Abstract][Full Text] [Related]
11. Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts.
Karakikes I; Hadri L; Rapti K; Ladage D; Ishikawa K; Tilemann L; Yi GH; Morel C; Gwathmey JK; Zsebo K; Weber T; Kawase Y; Hajjar RJ
Mol Ther; 2012 Mar; 20(3):565-71. PubMed ID: 22215018
[TBL] [Abstract][Full Text] [Related]
12. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
[TBL] [Abstract][Full Text] [Related]
13. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Desai AS; Barnard D; Bouchard A; Jaski B; Lyon AR; Pogoda JM; Rudy JJ; Zsebo KM
Lancet; 2016 Mar; 387(10024):1178-86. PubMed ID: 26803443
[TBL] [Abstract][Full Text] [Related]
14. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
Hulot JS; Salem JE; Redheuil A; Collet JP; Varnous S; Jourdain P; Logeart D; Gandjbakhch E; Bernard C; Hatem SN; Isnard R; Cluzel P; Le Feuvre C; Leprince P; Hammoudi N; Lemoine FM; Klatzmann D; Vicaut E; Komajda M; Montalescot G; Lompré AM; Hajjar RJ;
Eur J Heart Fail; 2017 Nov; 19(11):1534-1541. PubMed ID: 28393439
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy.
Katz MG; Fargnoli AS; Williams RD; Steuerwald NM; Isidro A; Ivanina AV; Sokolova IM; Bridges CR
J Thorac Cardiovasc Surg; 2014 Sep; 148(3):1065-72, 1073e1-2; discussion1072-3. PubMed ID: 25037619
[TBL] [Abstract][Full Text] [Related]
16. The preventive and therapeutic effects of AAV1-KLF4-shRNA in cigarette smoke-induced pulmonary hypertension.
Sun D; Ding D; Li Q; Xie M; Xu Y; Liu X
J Cell Mol Med; 2021 Jan; 25(2):1238-1251. PubMed ID: 33342082
[TBL] [Abstract][Full Text] [Related]
17. SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure.
Tilemann L; Lee A; Ishikawa K; Aguero J; Rapti K; Santos-Gallego C; Kohlbrenner E; Fish KM; Kho C; Hajjar RJ
Sci Transl Med; 2013 Nov; 5(211):211ra159. PubMed ID: 24225946
[TBL] [Abstract][Full Text] [Related]
18. Safety and long-term efficacy of AAV1.SERCA2a using nebulizer delivery in a pig model of pulmonary hypertension.
Watanabe S; Ishikawa K; Plataki M; Bikou O; Kohlbrenner E; Aguero J; Hadri L; Zarragoikoetxea I; Fish K; Leopold JA; Hajjar RJ
Pulm Circ; 2018; 8(4):2045894018799738. PubMed ID: 30129881
[TBL] [Abstract][Full Text] [Related]
19. Single SERCA2a Therapy Ameliorated Dilated Cardiomyopathy for 18 Months in a Mouse Model of Duchenne Muscular Dystrophy.
Wasala NB; Yue Y; Lostal W; Wasala LP; Niranjan N; Hajjar RJ; Babu GJ; Duan D
Mol Ther; 2020 Mar; 28(3):845-854. PubMed ID: 31981493
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
